time to release a new virus....
Pfizer, a key producer of the COVID-19 vaccine, has revised its earnings outlook for 2023, cutting its projected earnings per share and revenue estimates. The pharmaceutical titan recently announced a revised projected earnings per share (EPS) for FY23, cutting its previously projected $3.25-$3.45 range down to $1.45-$1.65. Furthermore, its FY23 revenue estimate has been adjusted from $67B-$70B to $58B-$61B.
Pfizer saw its 2022 revenue surpass a record $100 billion as company CEO Albert Bourla vowed that everyone will have a “perfectly normal life with just injection maybe once a year.” Bourla received a 36% pay hike and netted $33 million through the pandemic.
Despite four doses of his company’s vaccine, the quadruple-vaxxed Pfizer CEO still tested positive for COVID last year in August 2022. Bourla stated that he was “thankful” to have received four doses of the vaccine at the time.
Pfizer Takes Big Loss
Pfizer, a key producer of the COVID-19 vaccine, has revised its earnings outlook for 2023, cutting its projected earnings per share and revenue estimates. The pharmaceutical titan recently announced a revised projected earnings per share (EPS) for FY23, cutting its previously projected $3.25-$3.45 range down to $1.45-$1.65. Furthermore, its FY23 revenue estimate has been adjusted from $67B-$70B to $58B-$61B.
Pfizer saw its 2022 revenue surpass a record $100 billion as company CEO Albert Bourla vowed that everyone will have a “perfectly normal life with just injection maybe once a year.” Bourla received a 36% pay hike and netted $33 million through the pandemic.
Despite four doses of his company’s vaccine, the quadruple-vaxxed Pfizer CEO still tested positive for COVID last year in August 2022. Bourla stated that he was “thankful” to have received four doses of the vaccine at the time.
